| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| David Y Zhang, Yong Li, Syed M Abbas Rizvi, Changfa Qu, John Kearsley, Barry J Alle. Cytotoxicity of breast cancer cells overexpressing HER2/neu by 213Bi-Herceptin radioimmunoconjugate. Cancer letters. vol 218. issue 2. 2007-10-30. PMID:15670895. |
(213)bi-herceptin alpha conjugate (ac) was specifically cytotoxic to these cell lines in a her2 level-dependent fashion, resulting in the cellular death through apoptosis. |
2007-10-30 |
2023-08-12 |
human |
| Zhiming Mai, George L Blackburn, Jin-Rong Zho. Genistein sensitizes inhibitory effect of tamoxifen on the growth of estrogen receptor-positive and HER2-overexpressing human breast cancer cells. Molecular carcinogenesis. vol 46. issue 7. 2007-08-23. PMID:17295235. |
further determination of the molecular markers showed that tam and genistein combination synergistically induced bt-474 cell apoptosis in part by synergistic downregulation of the expression of survivin, one of the apoptotic effectors, and downregulation of egfr, her2, and eralpha expression. |
2007-08-23 |
2023-08-12 |
human |
| Marie P Piechocki, George H Yoo, Susan K Dibbley, Fulvio Lonard. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu. Cancer research. vol 67. issue 14. 2007-08-21. PMID:17638894. |
we characterized the effects of gefitinib on egfr, her2, and erbb-3 phosphorylation by western blot and determined the effects on downstream signaling through growth, survival, and stress pathways and the effect on proliferation, cell cycle, and apoptosis. |
2007-08-21 |
2023-08-12 |
Not clear |
| Tzong-Der Way, Jen-Kun Li. Role of HER2/HER3 co-receptor in breast carcinogenesis. Future oncology (London, England). vol 1. issue 6. 2007-07-31. PMID:16556064. |
the authors' research provides mechanistic evidence that apigenin induces apoptosis by depleting the her2 protein and, in turn, suppressing the signaling of the her2/her3-phosphatidylinositide 3-kinase/akt pathway. |
2007-07-31 |
2023-08-12 |
human |
| Konstantinos Drosopoulos, Alexander Pintza. Multifaceted targeting in cancer: the recent cell death players meet the usual oncogene suspects. Expert opinion on therapeutic targets. vol 11. issue 5. 2007-05-29. PMID:17465723. |
the authors overview the regulation of these factors and death receptor-induced apoptosis by classical oncogenes (e.g., ras, myc, her2) and their effectors/regulators, most of which are also being targeted. |
2007-05-29 |
2023-08-12 |
Not clear |
| Ping-Hui Tseng, Yu-Chieh Wang, Shu-Chuan Weng, Jing-Ru Weng, Chang-Shi Chen, Robert W Brueggemeier, Charles L Shapiro, Ching-Yu Chen, Sandra E Dunn, Michael Pollak, Ching-Shih Che. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor. Molecular pharmacology. vol 70. issue 5. 2006-12-04. PMID:16887935. |
here, we investigated the effect of osu-03012 on trastuzumab-mediated apoptosis in four breast cancer cell lines with different her2 expression and trastuzumab-resistance status, including mda-mb-231, bt474, skbr3, and insulin-like growth factor-i receptor-overexpressing skbr3 (skbr3/igf-ir). |
2006-12-04 |
2023-08-12 |
Not clear |
| Shinzaburo Noguch. Predictive factors for response to docetaxel in human breast cancers. Cancer science. vol 97. issue 9. 2006-10-18. PMID:16805818. |
various biological parameters have been studied clinically for their ability to predict response to docetaxel, such as parameters related to: (1) efflux (p-glycoprotein) and metabolism (cyp3a4); (2) beta-tubulin (somatic mutation of beta-tubulin and changes in beta-tubulin isotypes levels); (3) cell cycle (her2, brca1 and aurora-a); and (4) apoptosis (p53, bcl2 and thioredoxin). |
2006-10-18 |
2023-08-12 |
human |
| Shizhen Emily Wang, Archana Narasanna, Marianela Perez-Torres, Bin Xiang, Frederick Y Wu, Seungchan Yang, Graham Carpenter, Adi F Gazdar, Senthil K Muthuswamy, Carlos L Arteag. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer cell. vol 10. issue 1. 2006-09-11. PMID:16843263. |
knockdown of mutant her2 in h1781 lung cancer cells increased apoptosis and restored sensitivity to egfr tkis. |
2006-09-11 |
2023-08-12 |
Not clear |
| Lina Ekerljung, Ann-Charlott Steffen, Jorgen Carlsson, Johan Lennartsso. Effects of HER2-binding affibody molecules on intracellular signaling pathways. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. vol 27. issue 4. 2006-08-11. PMID:16651854. |
her2, which is overexpressed in 25-30% of human breast cancers, is a tyrosine kinase receptor critical for the signal transduction network that regulates proliferation, migration and apoptosis of cells. |
2006-08-11 |
2023-08-12 |
human |
| A P G Crijns, E W Duiker, S de Jong, P H B Willemse, A G J van der Zee, E G E de Vrie. Molecular prognostic markers in ovarian cancer: toward patient-tailored therapy. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. vol 16 Suppl 1. 2006-07-26. PMID:16515584. |
the prognostic role of key components of apoptotic and prosurvival pathways such as p53, egfr, and her2 has been extensively studied because resistance to chemotherapy is often caused by failure of tumor cells to go into apoptosis. |
2006-07-26 |
2023-08-12 |
Not clear |
| Marie P Piechocki, George H Yoo, Susan K Dibbley, Esmael H Amjad, Fulvio Lonard. Iressa induces cytostasis and augments Fas-mediated apoptosis in acinic cell adenocarcinoma overexpressing HER2/neu. International journal of cancer. vol 119. issue 2. 2006-07-14. PMID:16470840. |
we evaluated the effects of iressa on signal transduction networks downstream of the activated her2 and the impact on proliferation, cell cycle and apoptosis. |
2006-07-14 |
2023-08-12 |
mouse |
| Patrick J Perik, Winette T A Van der Graaf, Elisabeth G E De Vries, Frans Boomsma, Juergen Messerschmidt, Dirk J Van Veldhuisen, Dirk T Sleijfer, Jourik A Gietem. Circulating apoptotic proteins are increased in long-term disease-free breast cancer survivors. Acta oncologica (Stockholm, Sweden). vol 45. issue 2. 2006-07-05. PMID:16546863. |
circulating tumour necrosis factor (tnf) alpha, stnf-receptor (stnf-r) 1 and 2, sfas, sfas ligand, stnf-related apoptosis inducing ligand (strail) and serum her2 were measured with immunoassay. |
2006-07-05 |
2023-08-12 |
Not clear |
| Jean-François Mineo, Anne Bordron, Isabelle Quintin-Roué, Quintin-Roué Isabelle, Claude-Alain Maurage, Virginie Buhé, Buhé Virginie, Séverine Loisel, Loisel Séverine, François Dubois, Serge Blond, Christian Bertho. Increasing of HER2 membranar density in human glioblastoma U251MG cell line established in a new nude mice model. Journal of neuro-oncology. vol 76. issue 3. 2006-06-23. PMID:16200345. |
we have recently demonstrated the ability of anti-her2 antibodies to induce in vitro apoptosis gbm cell lines; this ability is correlated to her2 density. |
2006-06-23 |
2023-08-12 |
mouse |
| Irene Boeddinghaus, Stephen R D Johnso. Serial biopsies/fine-needle aspirates and their assessment. Methods in molecular medicine. vol 120. 2006-03-28. PMID:16491590. |
their assessment for biomarkers indicative of cellular proliferation, apoptosis, and endocrine response/resistance such as estrogen and progesterone receptor status, her2 and epidermal growth factor receptor are considered. |
2006-03-28 |
2023-08-12 |
Not clear |
| Masahito Shimizu, Atsuko Deguchi, Andrew K Joe, Judith F Mckoy, Hisataka Moriwaki, I Bernard Weinstei. EGCG inhibits activation of HER3 and expression of cyclooxygenase-2 in human colon cancer cells. Journal of experimental therapeutics & oncology. vol 5. issue 1. 2006-03-10. PMID:16416603. |
with a longer incubation time, 96 hours, a very low dose (1.0 microg/ml) of egcg also caused inhibition of cell growth, inhibition of activation of egfr, her2, and her3, a decrease in the levels of cox-2 and bcl-xl proteins, and apoptosis. |
2006-03-10 |
2023-08-12 |
human |
| C Bartholomeusz, H Itamochi, M Nitta, H Saya, M H Ginsberg, N T Uen. Antitumor effect of E1A in ovarian cancer by cytoplasmic sequestration of activated ERK by PEA15. Oncogene. vol 25. issue 1. 2006-02-07. PMID:16170361. |
the adenovirus type 5 gene e1a is known to suppress tumorigenicity by transcriptionally downregulating her-2/neu (her2) or by inducing apoptosis. |
2006-02-07 |
2023-08-12 |
Not clear |
| Hiroko Asanuma, Toshihiko Torigoe, Kenjiro Kamiguchi, Yoshihiko Hirohashi, Tousei Ohmura, Koichi Hirata, Masaaki Sato, Noriyuki Sat. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells. Cancer research. vol 65. issue 23. 2006-01-25. PMID:16322251. |
it was revealed that the survivin protein level was up-regulated by the coexpression of her2 and egfr, leading to the increased resistance against etoposide-induced apoptosis in breast cancer cells. |
2006-01-25 |
2023-08-12 |
human |
| Lenka Dubská, Ladislav Andera, Michael Allen Shear. HER2 signaling downregulation by trastuzumab and suppression of the PI3K/Akt pathway: an unexpected effect on TRAIL-induced apoptosis. FEBS letters. vol 579. issue 19. 2005-09-16. PMID:16023111. |
her2 signaling downregulation by trastuzumab and suppression of the pi3k/akt pathway: an unexpected effect on trail-induced apoptosis. |
2005-09-16 |
2023-08-12 |
Not clear |
| José Palacios, Emiliano Honrado, Ana Osorio, Alicia Cazorla, David Sarrió, Alicia Barroso, Sandra Rodríguez, Juan C Cigudosa, Orland Diez, Carmen Alonso, Enrique Lerma, Joaquín Dopazo, Carmen Rivas, Javier Beníte. Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers. Breast cancer research and treatment. vol 90. issue 1. 2005-05-19. PMID:15770521. |
markers analyzed included, amog others, common markers in breast cancer, such as hormone receptors, p53 and her2, along with 15 molecules involved in cell cycle regulation, such as cyclins, cyclin dependent kinases (cdk) and cdk inhibitors (cdki), apoptosis markers, such as bcl2 and active caspase 3, and two basal/myoepithelial markers (ck 5/6 and p-cadherin). |
2005-05-19 |
2023-08-12 |
Not clear |
| Yan-Ming Xu, Li-Feng Wang, Lin-Tao Jia, Xiu-Chun Qiu, Jing Zhao, Cui-Juan Yu, Rui Zhang, Feng Zhu, Cheng-Ji Wang, Bo-Quan Jin, Si-Yi Chen, An-Gang Yan. A caspase-6 and anti-human epidermal growth factor receptor-2 (HER2) antibody chimeric molecule suppresses the growth of HER2-overexpressing tumors. Journal of immunology (Baltimore, Md. : 1950). vol 173. issue 1. 2004-08-17. PMID:15210759. |
we demonstrate that the secreted immunocasp-6 molecule selectively recognizes and induces apoptosis in her2-overexpressing tumor cells in vitro, but not in cells with undetectable her2. |
2004-08-17 |
2023-08-12 |
mouse |